On June 26, 2024, the stockholders of NeuBase Therapeutics, Inc. voted to liquidate and dissolve the company. The Company has since filed a Certificate of Dissolution with the Secretary of State of the State of Delaware that is intended to effect the complete liquidation and dissolution of the company.
The wind-down activities necessary to complete the liquidation and dissolution are being conducted by the company's current Interim CEO and the sole director of the company’s board, working with various outside vendors, including attorneys and tax accountants.
The company intends to seek to distribute funds to our stockholders as quickly as possible, as permitted by Delaware corporate law and our Plan of Dissolution, and intends to take all reasonable actions to optimize the distributable value to our stockholders. However, we cannot predict with certainty the timing or amount of distributions, if any, to our stockholders.